Market News

Oclaro (OCLR) Market Value Declined While Matthews International Capital Management Upped by $1.06 Million Its Holding; As Sarepta Therapeutics I Com (SRPT) Market Value Rose, Benchmark Capital Advisors Increased Its Position

Benchmark Capital Advisors increased its stake in Sarepta Therapeutics I Com (SRPT) by 104% based on its latest 2017Q3 regulatory filing with the SEC. Benchmark Capital Advisors bought 10,400 shares as the company’s stock rose 22.49% with the market. The institutional investor held 20,400 shares of the health care company at the end of 2017Q3, valued at $925,000, up from 10,000 at the end of the previous reported quarter. Benchmark Capital Advisors who had been investing in Sarepta Therapeutics I Com for a number of months, seems to be bullish on the $4.16B market cap company. The stock increased 1.77% or $1.12 during the last trading session, reaching $64.34. About 678,824 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 96.82% since February 22, 2017 and is uptrending. It has outperformed by 80.12% the S&P500.

Matthews International Capital Management Llc increased its stake in Oclaro Inc (OCLR) by 20.64% based on its latest 2017Q3 regulatory filing with the SEC. Matthews International Capital Management Llc bought 132,100 shares as the company’s stock declined 22.87% while stock markets rallied. The institutional investor held 772,100 shares of the technology company at the end of 2017Q3, valued at $6.66M, up from 640,000 at the end of the previous reported quarter. Matthews International Capital Management Llc who had been investing in Oclaro Inc for a number of months, seems to be bullish on the $1.17B market cap company. The stock increased 0.15% or $0.01 during the last trading session, reaching $6.88. About 894,334 shares traded. Oclaro, Inc. (NASDAQ:OCLR) has risen 92.74% since February 22, 2017 and is uptrending. It has outperformed by 76.04% the S&P500.

Since October 3, 2017, it had 0 buys, and 1 sale for $575,000 activity.

Benchmark Capital Advisors, which manages about $225.46M and $128.79 million US Long portfolio, decreased its stake in General Motors Co (NYSE:GM) by 12,300 shares to 138,068 shares, valued at $5.58M in 2017Q3, according to the filing.

Investors sentiment increased to 2.88 in 2017 Q3. Its up 1.36, from 1.52 in 2017Q2. It improved, as 24 investors sold SRPT shares while 27 reduced holdings. 63 funds opened positions while 84 raised stakes. 51.70 million shares or 25.22% more from 41.29 million shares in 2017Q2 were reported. Schwab Charles Inv Mngmt owns 268,553 shares or 0.01% of their US portfolio. Pictet Asset Ltd has 36,400 shares. Lord Abbett And Com Ltd Liability Corp has invested 0.08% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Blackrock reported 6.23 million shares or 0.01% of all its holdings. Pura Vida Ltd Liability Com accumulated 50,000 shares. Hanson Mcclain Inc holds 0% or 699 shares in its portfolio. Moreover, Barclays Pcl has 0.01% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). 10,545 were reported by Employees Retirement Association Of Colorado. 4.94 million are owned by Vanguard Group. Oppenheimer Asset Mngmt stated it has 99 shares or 0% of all its holdings. California Employees Retirement Sys holds 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 142,900 shares. Hall Laurie J Trustee owns 130 shares for 0% of their portfolio. Laurion Cap Ltd Partnership invested 0.02% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Raymond James Advsr Incorporated reported 27,596 shares. Mark Sheptoff Planning Llc holds 100 shares.

Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 22 have Buy rating, 0 Sell and 5 Hold. Therefore 81% are positive. Sarepta Therapeutics had 103 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer on Thursday, July 20 with “Buy”. William Blair maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Friday, July 21 with “Buy” rating. As per Thursday, March 2, the company rating was upgraded by Leerink Swann. The company was upgraded on Tuesday, June 7 by Wedbush. Piper Jaffray downgraded the shares of SRPT in report on Monday, January 18 to “Neutral” rating. The company was initiated on Friday, October 23 by Jefferies. The firm earned “Buy” rating on Wednesday, September 6 by J.P. Morgan. As per Wednesday, August 26, the company rating was maintained by TH Capital. SunTrust maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Tuesday, September 1. SunTrust has “Neutral” rating and $36 target. The rating was upgraded by Cowen & Co on Tuesday, September 20 to “Outperform”.

Matthews International Capital Management Llc, which manages about $24.94B and $2.42 billion US Long portfolio, decreased its stake in Taiwan Semiconductor Mfg Ltd (NYSE:TSM) by 232,677 shares to 3.76M shares, valued at $141.09 million in 2017Q3, according to the filing. It also reduced its holding in Baozun Inc by 533,500 shares in the quarter, leaving it with 1.08 million shares, and cut its stake in Taro Pharmaceutical Inds Ltd (NYSE:TARO).

Leave a Reply

Your email address will not be published. Required fields are marked *